Your browser doesn't support javascript.
loading
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
Harding, James J; Garrido-Laguna, Ignacio; Chen, Xiaoying; Basu, Cynthia; Dowlati, Afshin; Forgie, Alison; Hooper, Andrea T; Kamperschroer, Cris; Max, Steven I; Moreau, Allison; Shannon, Megan; Wong, Gilbert Y; Hong, David S.
Afiliação
  • Harding JJ; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States.
  • Garrido-Laguna I; Huntsman Cancer Institute at University of Utah, Salt Lake City, UT, United States.
  • Chen X; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Basu C; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Dowlati A; University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States.
  • Forgie A; Early Clinical Development and Oncology Research, Worldwide Research and Development, Pfizer, San Francisco, CA, United States.
  • Hooper AT; Oncology Research and Development, Pfizer, Inc., Pearl River, NY, United States.
  • Kamperschroer C; Drug Safety Research and Development, Worldwide Research and Development, Pfizer, Groton, CT, United States.
  • Max SI; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Moreau A; Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, PA, United States.
  • Shannon M; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Wong GY; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Hong DS; Early Clinical Development and Oncology Research, Worldwide Research and Development, Pfizer, San Francisco, CA, United States.
Front Immunol ; 13: 845417, 2022.
Article em En | MEDLINE | ID: mdl-35493516
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Neoplasias Limite: Adult / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Neoplasias Limite: Adult / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos